On Safety and Pharmacoeconomics of Moxifloxacin in the Management of Urinogenital Infection

ZHANG Hegong,LI Yejun,DONG Chuanhai

DOI: https://doi.org/10.3969/j.issn.1672-2124.2007.02.020

2007-01-01

Abstract:OBJECTIVE: To observe the clinical efficacy and safety of moxifloxacin in the management of urinogenital infection and to conduct pharmacoeconomical analysis of this drug.METHODS: A total of 76 cases with urinogenital infections were enrolled(of which,22 were patients with cystitis,16 were with pyelonephritis,12 were with prostatitis,5 were with epididymis,15 were with gonococcal urethritis and 6 were with other urinary tract infections): 38(treatment group,ratio of male to female: 26 vs.12,aged at 45 13) were assigned to receive Moxifloxacin tablets 400 mg peros q.d.for 7 days,another 38(control group,ratio of male to female: 25 vs.13,aged at 45 12) to receive Gatifloxacin 0.2g iv gtt b.i.d.for 7 days.The 2 groups were observed with regard to clinical efficacy,bacteria clearance and adverse reactions;meanwhile,a cost-minimization analysis was performed on the 2 groups.RESULTS: The total response rates,bacteria clearance rates and incidences of adverse reaction in treatment group vs.in control group were 86.8%(33/38) vs.89.5%(34/38),91.3%(42/46) vs.92.0%(46/50) and 2.63%(1/38) vs.5.26%(2/38),respectively,showing no significance between the 2 groups(P0.05),but the medical fee in treatment group was significantly lower than in control group B(P0.01).CONCLUSION: For patients with urinogenital infection,oral administration of moxiloxacin is not only safe and effective,but also more economical and reasonable.